WEBULL
News
NRSN
0.8545
+2.42%
0.0202
NeuroSense Therapeutics Appoints Alzheimer's Expert Steven Arnold to Scientific Advisory Board
Reuters · 1h ago
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash
TipRanks · 1d ago
Weekly Report: what happened at NRSN last week (1229-0102)?
Weekly Report · 3d ago
Weekly Report: what happened at NRSN last week (1222-1226)?
Weekly Report · 12/29/2025 09:53
NeuroSense Unveils Favourable Safety Analysis Data Of PrimeC In NST-AD-001 Study For Alzheimer's
NASDAQ · 12/23/2025 08:37
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial
TipRanks · 12/22/2025 17:18
NeuroSense Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/22/2025 16:11
NeuroSense Therapeutics Price Target Maintained With a $14.00/Share by D. Boral Capital
Dow Jones · 12/22/2025 16:11
D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target
Benzinga · 12/22/2025 16:00
NeuroSense confirms favorable safety, tolerability of Prime C in Phase 2 study
TipRanks · 12/22/2025 14:25
NeuroSense Therapeutics' Analysis From Phase 2 NST-AD-001 Trial Of PrimeC Combination In Alzheimer's Demonstrates Favorable Tolerability For PrimeC
Benzinga · 12/22/2025 14:20
NEUROSENSE CONFIRMS FAVORABLE SAFETY AND TOLERABILITY OF PRIMEC IN AN ALZHEIMER'S PHASE 2 STUDY
Reuters · 12/22/2025 14:19
NeuroSense Reports PrimeC Shows Favorable Safety in Alzheimer's Phase 2 Trial
Reuters · 12/22/2025 14:18
Weekly Report: what happened at NRSN last week (1215-1219)?
Weekly Report · 12/22/2025 09:53
Weekly Report: what happened at NRSN last week (1208-1212)?
Weekly Report · 12/15/2025 09:58
Noble Financial Remains a Buy on Neurosense Therapeutics Ltd. (NRSN)
TipRanks · 12/09/2025 14:35
NeuroSense Therapeutics Locks Database For Phase 2 RoAD Study Of PrimeC In Alzheimer's; Topline Results Expected Q1 2026
Benzinga · 12/08/2025 19:11
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 12/08/2025 17:05
NeuroSense Completes Data Collection for Alzheimer’s Trial
TipRanks · 12/08/2025 13:27
NeuroSense Therapeutics Locks Database for Phase 2 Alzheimer's Trial with Topline Results Expected in 2026
Reuters · 12/08/2025 13:01
More
Webull provides a variety of real-time NRSN stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSN
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease